drugset / Trial / NCT03310580

Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension

NCT03310580

Phase 2 Completed 42 enrolled Aerie Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

To test the safety and effectiveness of AR-13324 0.02% and 0.04% ophthalmic solution relative to placebo in Japanese/Japanese-American subjects with open-angle glaucoma or ocular hypertension in US.

Timeline

Start
2017-11-15
Primary completion
2018-10-25
Completion
2018-10-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Netarsudil Small molecule 0.02 % Topical
Subject Netarsudil Small molecule 0.04 % Topical

Indications